FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD
Public ClinicalTrials.gov record NCT03846193. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
FOCUS: An Open Label First in Human Phase I/II Multicentre Study to Evaluate the Safety, Dose Response and Efficacy of GT005 Administered as a Single Subretinal Injection in Subjects With Macular Atrophy Due to AMD
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This was an open label first in human Phase I/II multicentre study of GT005 in subjects with Macular Atrophy due to Age-related macular degeneration (AMD).
Study identification
- NCT ID
- NCT03846193
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 56 participants
Conditions and interventions
Conditions
Interventions
- GT005 Biological
- GT005 / Device: Orbit™ Subretinal Delivery System Device
Biological · Device
Eligibility (public fields only)
- Age range
- 55 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 17, 2018 (Actual)
- Primary completion
- Jun 25, 2024 (Actual)
- Completion
- Jun 25, 2024 (Actual)
- Last update posted
- Jan 28, 2026
2018 – 2024
United States locations
- U.S. sites
- 7
- U.S. states
- 7
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Midwest Eye Institute | Indianapolis | Indiana | 46290 | — |
| Wolfe Eye Clinic | West Des Moines | Iowa | 50266 | — |
| Ophthalamic Consultants of Boston (OCB) | Boston | Massachusetts | 02114 | — |
| Pepose Vision Institute | Chesterfield | Missouri | 63017 | — |
| Sierra Eye Associates | Reno | Nevada | 89502 | — |
| Cincinnati Eye Institute | Cincinnati | Ohio | 45242 | — |
| Mid-Atlantic Retina | Philadelphia | Pennsylvania | 19107 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03846193, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 28, 2026 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03846193 live on ClinicalTrials.gov.